Product name:CIPROFLOXACIN®
Company name:
DIN:03605746
Status:Marketed
Status date:2009-03-16
| Active ingredient(s) | Strength |
|---|---|
| 0.2% |
Click on a resource to visit a page with more information. You may be taken away from this page to a different Government of Canada website.
For consumers| Resource | Description |
|---|---|
The Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use. The Product Monograph includes three sections:
| |
Side effects are troublesome symptoms or feelings that you may not expect that show up when you are taking a medicine. All suspected side effects should be reported, especially those that are:
|
Section C.01.020.1 of the Food and Drug Regulations and section 62 of the Medical Devices Regulations, require hospitals to report to Health Canada all serious adverse drug reactions (ADRs) and medical device incidents (MDIs) within 30 days of being documented within the hospital. This regulatory requirement only applies to hospitals. |
| After Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes. |
Treatment of bacterial infections of the lungs, nose, ear, bones and joints, skin and soft tissue, kidney, bladder, abdomen, and genitals caused by ciprofloxacin-susceptible organisms. Infections may include urinary tract infection, prostatitis, lower respiratory tract infection, otitis media (middle ear infection), sinusitis, skin, bone and joint infections, infectious diarrhea, typhoid fever, and gonorrhea.
May be taken with or without food. May be taken w/ meals to minimise GI discomfort. Do not take w/ antacids, Fe or dairy products.
Hypersensitivity to ciprofloxacin or other quinolones. History or risk of QT prolongation; known history of myasthenia gravis. Concomitant use with tizanidine.
Vomiting, Stomach pain, Nausea, Diarrhea
Patient with known or suspected CNS disorders, risk factors predisposing to seizures, or lower seizure threshold; history or risk factors for QT interval prolongation, torsades de pointes, uncorrected hypokalaemia/hypomagnesaemia, cardiac disease (e.g. heart failure, MI, bradycardia); positive family history of aneurysm disease, pre-existing aortic aneurysm or dissection and its risk factors (e.g. Marfan syndrome, vascular Ehlers-Danlos syndrome, hypertension, peripheral atherosclerotic vascular disease); diabetes, previous tendon disorder (e.g. rheumatoid arthritis), G6PD deficiency. Renal and hepatic impairment. Elderly, children. Pregnancy and lactation.
Store between 20-25°C.
Quinolones
uses a ciprofloxacin-susceptible mechanism. It inhibits the bacterial DNA gyrase and topoisomerase IV and results in the closure of the bacterial bacterial DNA gyrase and topoisomerase IV and the relaxation of the bacterial bacterial DNA. This leads to a reduction in the population of bacteria that are ciprofloxacin-sensitive, ultimately resulting in a greater number of live bacteria. The topoisomerase IV enzyme is required for the replication of bacterial DNA. The most common side-effects are erythema, conjunctival redness, fever, depression, hypotonia (slow breathing), tachycardia, urinary retention, urinary tract infection, pharyngitis, hypomagnesaemia, skin reactions, including generalised back pain, nausea, exudations, maculopapular jaundice, thrombocytopeyal reaction, and bone pain. erythema with eosinophilia erythematous or thrombocytopenia with eosinophilia ello- maculoplasmin. There are no specific side-effects profile for this class of antibacterial drugs. Its use in the management of acute exacerbation of chronic bronchitis is contraindicated. The Food and Drug Administration (FDA) has not approved this drug. concomitant use with fluoroquinolone antibiotics. clarithromycin class B anti-tuberculosis antibiotics. erythromycin class C antidepressants. clarithromycin class A antipsychotic antibiotics. efavirenz class D antidepressants. erythromycin quinolones.The most common side-effects are erythema, conjunctivitis, rash, photosensitivity, and nephrotic syndrome. In case of similar side-effects, seek medical advice promptly.
Serious side effectsIn case of severe side-effects, discontinue use and seek medical help. Patient should inform their healthcare provider promptly.Ciprofloxacin (Cipro) is an antibiotic medication commonly used to treat a variety of bacterial infections. It works by killing the bacteria's ability to produce and multiply, leading to fewer side effects compared to older antibiotics.
Bacterial infections can be caused by various bacteria, includingStreptococcus pneumoniae,Haemophilus influenzae, andStaphylococcus aureus.
The main bacteria causing bacterial infections areStreptococcus pyogenesStreptococcus agal growing
WhileStreptococcusis known to be the most effective,Staphylococcusis also a common cause of ear infections. Other causes of ear infections areCommon strains of bacteria are also found in these ear infections.
Ciprofloxacin (Cipro) is effective against a wide range of bacterial infections, including middle ear infections, tonsilitis, and sinusitis. It belongs to the fluoroquinolone class of antibiotics.
The medication can also be used for conditions such as lower respiratory tract infections, urinary tract infections, sinusitis, and otitis media. It is particularly beneficial for people who cannot tolerate or have trouble breathing.
Fluoroquinolones, commonly known asFQAs, are commonly prescribed to treat bacterial infections. They include ciprofloxacin (Cipro), levofloxacin (Levaquin), moxifloxacin (Bactazone), and ofloxacin (Avelox).
While there are over 100 types of fluoroquinolone antibiotics, they are classified as either fluoroquinolone-based or ciprofloxacin-based antibiotics. They are typically prescribed by a healthcare provider based on a variety of factors, including the type of infection being treated.
Fluoroquinolones are also used to treatpneumonia(pneumonia that is caused by a bacteria),Acute uncomplicated skin infections(from a bacterium), andCommunity-acquired pneumonia(from a bacteria).
These infections are often treated with antibiotics like ciprofloxacin, which are commonly used to treatandcommunity-acquired pneumoniainfections. The medication is typically taken orally, but the dosage and duration can vary depending on the type of infection and the severity of symptoms. The medication is typically taken every 4–6 hours, with or without food, for 5 days.
While ciprofloxacin is effective against a wide range of bacterial infections, it can also be used for certain conditions, including ear infections. Here are some specific uses for ciprofloxacin for ear infections:
The US Food and Drug Administration (FDA) is warning consumers about a potentially serious, potentially fatal side effect associated with Ciprofloxacin. The drug, known generically as ciprofloxacin, was approved for use in adults over the age of 18 who are at least 50 years old. Ciprofloxacin, marketed as Cipro (ciprofloxacin), is a fluoroquinolone antibiotic, which is used to treat bacterial infections. Ciprofloxacin is the most commonly prescribed antibiotic in the US.
The FDA warned consumers that taking ciprofloxacin could lead to serious side effects, including:
The FDA issued a statement Friday saying that it is working with healthcare providers to prevent such side effects.
“While the FDA has not identified a specific reason for the serious side effects associated with Ciprofloxacin, it has been reported that some patients taking the drug have experienced liver damage, which can be fatal,” the FDA said in its statement. “Patients should be advised to contact their healthcare provider if they have any symptoms of liver damage.”
Ciprofloxacin can be taken with or without food. The drug can also be taken by mouth.
In a statement, the FDA said that it is working with healthcare providers to identify any patients who may have experienced a reaction to the drug. “Healthcare providers are working closely with patients to develop a plan for appropriate and safe use of the drug,” the statement said.
The agency also said that some patients who are taking Ciprofloxacin have reported experiencing nausea, vomiting, loss of appetite, and rash.
In a statement, the FDA said that it is working with healthcare providers to advise patients on the most effective way to treat the symptoms of SJS. The FDA also said that some patients who are taking Ciprofloxacin have reported experiencing nausea, vomiting, loss of appetite, and rash.
“The risk of SJS symptoms, including nausea and vomiting, is higher in patients who are elderly, pregnant, or breastfeeding, and in those who are taking other antibiotics,” the agency said.
“Patients should be advised to contact their healthcare provider if they have any symptoms of liver damage,” the FDA added.“Ciprofloxacin should not be used to treat serious bacterial infections, including SJS, due to the risk of serious side effects.”“Patients should be advised to contact their healthcare provider if they experience symptoms of liver damage, including nausea, vomiting, and skin rashes,” the FDA said.
The agency said that some patients who are taking Ciprofloxacin have reported experiencing nausea, vomiting, loss of appetite, and rash.
“Patients should be advised to contact their healthcare provider if they experience symptoms of liver damage, including nausea and vomiting,” the FDA added.
“Patients should be advised to contact their healthcare provider if they experience nausea, vomiting, skin rashes, and liver damage,” the FDA said.“Patients should be advised to contact their healthcare provider if they experience nausea, vomiting, skin rashes, liver damage, or liver failure,” the FDA said.“Patients should be advised to contact their healthcare provider if they experience nausea, vomiting, skin rashes, or liver failure,” the FDA said.Ciprofloxacin can interact with other medications, including some antibiotics and antifungals. A warning about the drug is also included in the product packaging.
Ciprofloxacin may be taken with or without food.
AstraZeneca has announced the successful launch of its Abbreviated New Drug Application (ANDA) for ciprofloxacin, which is the first of the new class of antibiotic generics approved in the United States by the US Food and Drug Administration (FDA).
Ciprofloxacin is indicated for the treatment of serious bacterial infections of the urinary tract, respiratory system, skin, and soft tissue, including:
Ciprofloxacin has been approved for the treatment of uncomplicated gonorrhea, particularly in patients with chlamydia and rectal and genital tract infections.
For further information about ciprofloxacin please visit.
© 2025 LYNN 2025, All rights reserved.
Stade de France Pharmacy